Rigshospitalet
Department of Radiation Biology

Kirsten Grunnet, Registered Nurse

Title: Research Nurse
Email: kirsten.grunnet@rh.regionh.dk
Phone: (+45) 35 45 63 02
Fax: (+45) 35 45 63 01
 
Date of Birth:

December 26th, 1958

Current Position:

Research Nurse

Education:

2003-2004: Education as Advanced Cancer Nurse
1979-1983: Nursing School, Copenhagen University Hospital, Denmark
1975-1978: High School, Buddinge Gymnasium, Denmark

Professional Experiences:
2006-Research Nurse, Department of Radiation Biology, Copenhagen
University Hospital, Denmark
2001-Staff Nurse, Department of Oncology, Copenhagen University Hospital, Denmark  
1995-2001Staff Nurse, Department of Liver Transplantation, Copenhagen University Hospital,
Denmark
1990-1995Staff Nurse, Department of Hepatology, Copenhagen University Hospital,
Denmark  
1983-1990Staff Nurse, Department of Gastroenterology, Copenhagen University
Hospital, Denmark
 
Conferences and Meetings:
 
Poster precentation
2013 The 4th Quadrennial Meeting of the World Federation of Neuro-Oncology and The18th Annual SNO Scientific Meeting and Education Day, San Francisco, Californien, USA;Michaelsen SR,  Christensen IJ, Grunnet K, Stockhausen MT, Broholm H,Kosteljanetz M, Poulsen HS;"A model for survival from glioblastoma multiforme in a cohort of consecutive non-selected patients from a single institution." 
 
Publications with peer-review
1.
Poulsen HS, Grunnet K, Sorensen M, Olsen P, Hasselbalch B, Nelausen K, Kosteljanetz M, Lassen U. Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours.
Acta Oncol. 2009;48(1):52-8.
2.Hasselbalch B, Eriksen JG, Broholm H, Christensen IJ, Grunnet K, Horsman MR, Poulsen HS, Stockhausen MT, Lassen U:Prospective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan. APMIS. 2010 Aug;118(8):585-94.
3.
Møller S, Grunnet K, Hansen S, Schultz H, Holmberg M, Sorensen M, Poulsen HS, Lassen U: A phase II trial with bevacizumab and irinotecanfor patients with primary brain tumors and progression after standard therapy.
Acta Oncol. Jul;51(6):797-804, 2012.
4.
Muhic A, Poulsen HS, Sorensen M, Grunnet K, Lassen U: Phase II Open-label Study of Nintedanib in Patients with Recurrent Glioblastoma Multiforme.
J Neurooncol. 2013 Jan;111(2):205-12.
5.Michaelsen SR, Christensen IJ, Grunnet K, Stockhausen MT, Broholm H, Kostaljanetz M, Poulsen HS: Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme in a cohort of consecutive non-selected patients from a single institution. 2013 Sep 3;13(1):402.
6.Hofland KF, Hansen S, Sorensen M, Schultz HP, Muhic A, Engelholm S, Grunnet K, Ask A, Kristiansen C, Thomsen C, Poulsen HS, Lassen U: Neoadjuvant Bevacizumab and Irinotecan versus Bevacizumab and Temozolomide followed by Concomitant Chemoradiotherapy in Newly Diagnosed Glioblastoma Multiforme: A Randomized Phase II Study. Acta Oncol. 2014 Jan 23.
7.Urup T, Dahlrot RH, Grunnet K, Christensen IJ, Michaelsen SR, Toft A, Larsen VA, Broholm H, Kosteljanetz M, Hansen S, Poulsen HS, Lassen U: Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecants treated with bevacizumab and irinotecan. Acta Oncol 2015. Acta Oncol. 2016 Feb 1:1-5.
8.Kristensen LS, Michelsen SR, Dyrbye H, Aslan D, Grunnet K, Christensen IJ, Poulsen HS, Grønbæk K, Broholm H: Assessment of quantitative and allelic MGMT methylation patterns as a prognostic marker in glioblastoma. J Nucl Med. 2015 Oct 1.
9.Poulsen SH, Urup T, Grunnet K, Christensen IJ, Larsen VA, Rosenschöld PM, Poulsen HS, Law I: The prognostic value of radiotherapy planning O-(2-18F-fluoroethyl)-L-tyrosine PET in newly diagnosed glioblastoma. Eur J Nucl Med Mol Imaging. 2016 Aug 23, PMID: 27554774
10.Urup T, Michaelsen SR, Rønn Olsen LR,Toft A, Christensen IJ, Grunnet K, Winther O, Broholm H, Kosteljanetz M, Issazadeh-Navikas S, Poulsen HS, Lassen U: Angiotensinogen and HLA Class II Predict Bevacizumab Response in Recurrent Glioblastoma Patients. Molecular Oncology.Mol Oncol. 2016 Oct; 10(8):1160-8. doi: 10.1016. PMID: 27262894.
11.Jakobsen JN, Urup T, Grunnet K, Toft A, Johansen MD, Poulsen SH, Christensen IJ, Poulsen HS, Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients. J Neurooncol. 2018 Apr;137(2):439-446. doi: 10.1007/s11060-017-2736-x. Epub 2018 Jan 12.PMID: 29330749
12.Toft A, Urup T, Christensen IJ, Michaelsen SR, Lukram B, Grunnet K, Kosteljanetz M, Larsen AVA, Lassen U, Broholm H, Poulsen HS: Predictive and Prognostic Biomarkers in Recurrent WHO Grade III Glioma Patients Treated with Bevacizumab and Irinotecan.Cancer Invest. 2018 Feb 7;36(2):165-174. doi: 10.1080/07357907.2018.1430818. Epub 2018 Feb 2. Review. PMID: 29393706
 



.

 

 

 

 

The Finsencenter, Section 6321, Copenhagen University Hospital, Blegdamsvej 9, DK-2100 Copenhagen, Denmark